Neogenomics Soars 18.07% on Patent Win

On August 29, 2025, Neogenomics' stock surged by 18.07% in pre-market trading, marking a significant rise that has caught the attention of investors and analysts alike.

Neogenomics recently secured a major victory in a patent infringement lawsuit against Natera. The District Court for the Middle District of North Carolina granted NeoGenomics' motion for summary judgment, invalidating all of Natera's asserted patent claims for claiming ineligible subject matter. This ruling allows NeoGenomics to continue commercializing its RaDaR ST molecular residual disease (MRD) assay without legal hindrance.

The court's decision is a significant milestone for NeoGenomics, as it reinforces the company's commitment to providing comprehensive diagnostic testing options for cancer patients. The RaDaR ST assay, which has been launched to biopharma customers, is now being submitted to the Centers for Medicare & Medicaid Services' Molecular Diagnostic Services Program for clinical reimbursement coverage.

Tony Zook, CEO of NeoGenomics, expressed satisfaction with the court's decision, emphasizing the company's dedication to innovation and patient care. He stated that NeoGenomics will continue to protect and defend its intellectual property to drive future advancements in cancer diagnostics.